ArticleProceedings of the National Academy of Sciences of the United States of America2016
Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 358 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
358 citing papers in PubMed, 3 syntheses or guidelines pooled it, 592 citations in OpenAlex.
- The increasing complexity of arbovirus serology: An in-depth systematic review on cross-reactivity.PLoS neglected tropical diseases · 2023Pooled it
- Recent Advances in Biosensors for Detection of COVID-19 and Other Viruses.IEEE reviews in biomedical engineering · 2023Pooled it
- Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned.PLoS neglected tropical diseases · 2019Pooled it
- Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans.Nature microbiology · 2025Trial
- Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection.The Journal of infectious diseases · 2023Trial
- Persistence of Immune Responses With an Inactivated Japanese Encephalitis Single-Dose Vaccine, JENVAC and Interchangeability With a Live-Attenuated Vaccine.The Journal of infectious diseases · 2020Trial
- Multiple, but not isolated, yellow fever virus-associated orthoflavivirus immune histories drive antibody-dependent enhancement of Zika and dengue viruses.medRxiv : the preprint server for health sciences · 2026Article
- Identification of a capsid-derived Zika virus epitope with high IgG discriminatory performance.Archives of virology · 2026Article
- IgG3 Hinge Architecture Expands Dengue Virus Breadth of A Quaternary Epitope Dependent Zika Virus Cross-Neutralizing Antibody.bioRxiv : the preprint server for biology · 2026Article
- Improved and customized dengue serodiagnostics through combined NS1/IgM testing and novel dual-cut-off IgG ELISA.PLoS neglected tropical diseases · 2026Article
- Integrative immunogenomic strategy for designing a multi-epitope vaccine against Zika and Dengue viruses.Scientific reports · 2026Article
- Mathematical modeling of sequential Dengue-Zika infections: dynamic insights into antibody-dependent enhancement and neutralization effects.Scientific reports · 2026Article
- Ten years of Zika in Brazil: achievements, challenges and perspectives.Virology journal · 2026Review
- The Squalene Oil-in-Water Nanoemulsion Vaccine Carrier AddaVax Potentiates TLR-Induced B-Cell Responses.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2026Article
- Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026Review
- Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk.Nature communications · 2025Article
- Ultra-sensitive fluorescent detection of DENV-2 Nucleocapsid Protein 1 based on CDs-Eu@ZIF-8 modified FeMikrochimica acta · 2025Article
- Detection and Validation of Influenza Virus Hemagglutinin Specific, Cross-Reactive, and Heteroclitic B Cells Induced by a Combination Vaccine Adjuvant.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2025Article
- Review
- Review
298 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus of significant public health concern. ZIKV shares a high degree of sequence and structural homology compared with other flaviviruses, including dengue virus (DENV), resulting in immunological cross-reactivity. Improving our current understanding of the extent and characteristics of this immunological cross-reactivity is important, as ZIKV is presently circulating in areas that are highly endemic for dengue. To assess the magnitude and functional quality of cross-reactive immune responses between these closely related viruses, we tested acute and convalescent sera from nine Thai patients with PCR-confirmed DENV infection against ZIKV. All of the sera tested were cross-reactive with ZIKV, both in binding and in neutralization. To deconstruct the observed serum cross-reactivity in depth, we also characterized a panel of DENV-specific plasmablast-derived monoclonal antibodies (mAbs) for activity against ZIKV. Nearly half of the 47 DENV-reactive mAbs studied bound to both whole ZIKV virion and ZIKV lysate, of which a subset also neutralized ZIKV. In addition, both sera and mAbs from the dengue-infected patients enhanced ZIKV infection of Fc gamma receptor (FcγR)-bearing cells in vitro. Taken together, these findings suggest that preexisting immunity to DENV may impact protective immune responses against ZIKV. In addition, the extensive cross-reactivity may have implications for ZIKV virulence and disease severity in DENV-experienced populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.